1
|
Haddad JE, Sabbakh NA, Macaron MM, Shaaban H, Bourdakos NE, Shi A, Saad B, Nakanishi H, Than CA, Daoud YJ. NSAIDs and Corticosteroids for the Postoperative Management of Age-Related Cataract Surgery: A Systematic Review and Meta-analysis. Am J Ophthalmol 2024; 260:1-13. [PMID: 37797866 DOI: 10.1016/j.ajo.2023.09.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2023] [Revised: 09/10/2023] [Accepted: 09/27/2023] [Indexed: 10/07/2023]
Abstract
PURPOSE To evaluate the safety and efficacy of non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids in the postoperative management of cataract surgery for age-related cataract in adults. DESIGN Meta-analysis. METHODS Cochrane, Embase, PubMed, Scopus, Web of Science and CINAHL were searched for articles using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) system. The review was registered prospectively with PROSPERO (CRD42022364733). Randomized controlled trials of patients undergoing age-related cataract surgery treated with corticosteroids, NSAIDs, or a combination were included. RESULTS A total of 19 studies were included, with 3473 patients (3638 eyes) treated following cataract surgery with NSAIDs (n = 1479), corticosteroids (n = 1307), or a combination (n = 687). Combination treatment demonstrated favorable best-corrected visual acuity compared to corticosteroids 4 to 6 weeks postoperatively (MD = -0.01 logMAR, 95% CI: -0.02, -0.01, I2 = 0%). NSAIDs had more favorable flare values than corticosteroids on day 7 (MD = -9.17 photons/ms, 95% CI = -16.52, -1.82, I2 = 94%), day 14 (MD = -5.23 photons/ms, 95% CI = -8.35, -2.11, I2 = 94%), and 4 to 6 weeks (MD = -1.62 photons/ms, 95% CI = -3.03, -0.20, I2 = 93%) postoperatively. Furthermore, 4 to 8 weeks postoperatively, patients treated with NSAIDs showed lower central macular thickness (MD = -13.26 µm, 95% CI = -18.66, -7.86, I2 = 81%) compared to those treated with corticosteroids. NSAIDs and combination treatment were associated with a lower incidence of central macular edema (OR = 0.16, 95% CI = 0.07, 0.35, I2 = 61%; OR = 0.21, 95% CI = 0.10, 0.45, I2 = 31%) than corticosteroids 4 to 8 weeks postoperatively. CONCLUSIONS NSAIDs and combination treatments could be regarded as more effective and safer alternatives to corticosteroids alone in the postoperative management of cataract surgery. Further studies should be conducted to determine why this evidence has not been reflected in practice patterns, and to further compare the effectiveness of NSAIDs and combination treatments.
Collapse
Affiliation(s)
- Joe El Haddad
- From the St George's University of London (J.E.H., N.A.S., M.M.M., H.S., N.E.B., A.S., B.S., H.N., C.A.T.), London, UK; University of Nicosia Medical School (J.E.H., N.A.S., M.M.M., H.S., N.E.B., A.S., B.S., H.N., C.A.T.), University of Nicosia, Nicosia, Cyprus
| | - Nader Al Sabbakh
- From the St George's University of London (J.E.H., N.A.S., M.M.M., H.S., N.E.B., A.S., B.S., H.N., C.A.T.), London, UK; University of Nicosia Medical School (J.E.H., N.A.S., M.M.M., H.S., N.E.B., A.S., B.S., H.N., C.A.T.), University of Nicosia, Nicosia, Cyprus
| | - Marie Michele Macaron
- From the St George's University of London (J.E.H., N.A.S., M.M.M., H.S., N.E.B., A.S., B.S., H.N., C.A.T.), London, UK; University of Nicosia Medical School (J.E.H., N.A.S., M.M.M., H.S., N.E.B., A.S., B.S., H.N., C.A.T.), University of Nicosia, Nicosia, Cyprus
| | - Hashim Shaaban
- From the St George's University of London (J.E.H., N.A.S., M.M.M., H.S., N.E.B., A.S., B.S., H.N., C.A.T.), London, UK; University of Nicosia Medical School (J.E.H., N.A.S., M.M.M., H.S., N.E.B., A.S., B.S., H.N., C.A.T.), University of Nicosia, Nicosia, Cyprus
| | - Natalie E Bourdakos
- From the St George's University of London (J.E.H., N.A.S., M.M.M., H.S., N.E.B., A.S., B.S., H.N., C.A.T.), London, UK; University of Nicosia Medical School (J.E.H., N.A.S., M.M.M., H.S., N.E.B., A.S., B.S., H.N., C.A.T.), University of Nicosia, Nicosia, Cyprus
| | - Ao Shi
- From the St George's University of London (J.E.H., N.A.S., M.M.M., H.S., N.E.B., A.S., B.S., H.N., C.A.T.), London, UK; University of Nicosia Medical School (J.E.H., N.A.S., M.M.M., H.S., N.E.B., A.S., B.S., H.N., C.A.T.), University of Nicosia, Nicosia, Cyprus
| | - Baraa Saad
- From the St George's University of London (J.E.H., N.A.S., M.M.M., H.S., N.E.B., A.S., B.S., H.N., C.A.T.), London, UK; University of Nicosia Medical School (J.E.H., N.A.S., M.M.M., H.S., N.E.B., A.S., B.S., H.N., C.A.T.), University of Nicosia, Nicosia, Cyprus
| | - Hayato Nakanishi
- From the St George's University of London (J.E.H., N.A.S., M.M.M., H.S., N.E.B., A.S., B.S., H.N., C.A.T.), London, UK; University of Nicosia Medical School (J.E.H., N.A.S., M.M.M., H.S., N.E.B., A.S., B.S., H.N., C.A.T.), University of Nicosia, Nicosia, Cyprus
| | - Christian A Than
- From the St George's University of London (J.E.H., N.A.S., M.M.M., H.S., N.E.B., A.S., B.S., H.N., C.A.T.), London, UK; University of Nicosia Medical School (J.E.H., N.A.S., M.M.M., H.S., N.E.B., A.S., B.S., H.N., C.A.T.), University of Nicosia, Nicosia, Cyprus; School of Biomedical Sciences (C.A.T.), The University of Queensland, St Lucia, Australia
| | - Yassine J Daoud
- The Wilmer Eye Institute (Y.J.D.), The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.
| |
Collapse
|
2
|
Taghe S, Mirzaeei S, Bagheri M. Preparation of polycaprolactone and polymethacrylate nanofibers for controlled ocular delivery of ketorolac tromethamine: Pharmacokinetic study in Rabbit's Eye. Eur J Pharm Sci 2024; 192:106631. [PMID: 37951316 DOI: 10.1016/j.ejps.2023.106631] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2023] [Revised: 10/18/2023] [Accepted: 11/08/2023] [Indexed: 11/13/2023]
Abstract
Ophthalmitis is an inflammation of the eye triggered by various conditions including diseases, allergy, trauma, or surgery. Management of this condition usually includes administration of topical anti-inflammatory eye drops such as nonsteroidal anti-inflammatory drugs. To overcome the challenges of conventional eye drops such as frequent administration and low intraocular bioavailability, nanofibrous inserts of Ketorolac tromethamine (KET) were developed in this study. Polycaprolactone and polymethacrylate containing KET were electrospun to prepare biocompatible and biodegradable nanofibers. The inserts were studied for morphology, drug-polymer interaction, physicochemical properties, cell viability, in vitro drug release study and pharmacokinetic study in rabbit's eye. Uniform nanofibers with mean diameters < 350 nm were developed. Suitable mechanical properties with tensile strength up to 2.8 MPa indicated high strength and flexibility of inserts. Nanofibers exhibited controlled drug release for up to 140 h at a concentration more than 50 μg/ml in tears without causing any damage or irritation to the eye. Formulations indicated enhanced pharmacokinetics with 6- to 8-times higher Area Under the Curve (AUC0-144) compared to KET eye drop. Acceptable cell viability confirmed the safety of inserts. Due to the fact that this preservative-free polymer insert can obtain therapeutic concentration in the tear film without fluctuation, it can be a suitable alternative for the treatment of intraocular inflammations with less complications, easier use, and even higher intraocular penetration.
Collapse
Affiliation(s)
- Shiva Taghe
- Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran; Pharmaceutical Sciences Research Center, Rahesh Daru Novine, Kermanshah 6715847141, Iran; Nano Drug Delivery Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
| | - Shahla Mirzaeei
- Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran; Pharmaceutical Sciences Research Center, Rahesh Daru Novine, Kermanshah 6715847141, Iran; Nano Drug Delivery Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.
| | - Masood Bagheri
- Clinical Research Development Center, Imam Khomeini and Mohammad Kermanshahi and Farabi Hospitals, Kermanshah University of Medical Sciences, Kermanshah, Iran; Department of Ophthalmology, Imam Khomeini Eye Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
| |
Collapse
|